Systemic treatment can be recommended in widespread disease (affecting multiple body areas) or in patients with a single area with large involvement and significant inflammation
doi: 10.1038/s41467-019-09915-2 63 HonoratoL.BonillaJ
On safety, the picture is reassuring within the studied context
It was marketed under the brand name Byetta and got approval in 2005
AOD9604 has been characterised across pre-clinical, safety pharmacology, and early-phase clinical research since the late 1990s, with peer-reviewed publications spanning lipid metabolism, adipose biology, joint repair, and bioavailability
Heavy Metals No heavy metals were detected, although this was not a particularly useful assay for this type of product